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Background: Mobility and sensorimotor inhibition impairments are heterogeneous in
Parkinson’s disease (PD). Genetics may contribute to this heterogeneity since the
apolipoprotein (APOE) ε4 allele and glucocerebrosidase (GBA) gene variants have been
related to mobility impairments in otherwise healthy older adult (OA) and PD cohorts. The
purpose of this study is to determine if APOE or GBA genetic status affects sensorimotor
inhibition and whether the relationship between sensorimotor inhibition and mobility
differs in genetic sub-groups of PD.
Methods: Ninety-three participants with idiopathic PD (53 non-carriers; 23 ε4 carriers;
17 GBA variants) and 72 OA (45 non-carriers; 27 ε4 carriers) had sensorimotor
inhibition characterized by short-latency afferent inhibition. Mobility was assessed in four
gait domains (pace/turning, rhythm, trunk, variability) and two postural sway domains
(area/jerkiness and velocity) using inertial sensors.
Results: Sensorimotor inhibition was worse in the PD than OA group, with no
effect of genetic status. Gait pace/turning was slower and variability was higher
(p < 0.01) in PD compared to OA. Postural sway area/jerkiness (p < 0.01) and
velocity (p < 0.01) were also worse in the PD than OA group. Genetic status
was not significantly related to any gait or postural sway domain. Sensorimotor
inhibition was significantly correlated with gait variability (r = 0.27; p = 0.02) and trunk
movement (r = 0.23; p = 0.045) in the PD group. In PD non-carriers, sensorimotor
inhibition related to variability (r = 0.35; p = 0.010) and trunk movement (r = 0.31;
p = 0.025). In the PD ε4 group, sensorimotor inhibition only related to rhythm (r = 0.47;
p = 0.024), while sensorimotor inhibition related to pace/turning (r = −0.49; p = 0.046)
and rhythm (r = 0.59; p = 0.013) in the PD GBA group. Sensorimotor inhibition
was significantly correlated with gait pace/turning (r = −0.27; p = 0.04) in the OA
group. There was no relationship between sensorimotor inhibition and postural sway.
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Conclusion: ε4 andGBA genetic status did not affect sensorimotor inhibition or mobility
impairments in this PD cohort. However, worse sensorimotor inhibition was associated
with gait variability in PD non-carriers, but with gait rhythm in PD ε4 carriers and with gait
rhythm and pace in PD with GBA variants. Impaired sensorimotor inhibition had a larger
effect on mobility in people with PD than OA and affected different domains of mobility
depending on genetic status.
Keywords: short-latency afferent inhibition, SAI, postural sway, balance, gait, GBA, APOE
INTRODUCTION
Mobility impairment is intrinsically linked to Parkinson’s
disease (PD). The severity of mobility impairment in PD is
heterogeneous, suggesting that underlying factors that play a role
in mobility impairment. In addition to basal ganglia dysfunction,
people with PD exhibit reduced cortical sensorimotor inhibition
as assessed by short-latency afferent inhibition (SAI) with
transcranial magnetic stimulation (TMS) (1–3). However, these
studies reveal inconsistencies regarding the impact of disrupted
sensorimotor inhibition on mobility disability in people with PD.
Sensorimotor inhibition is associated with decreased gait
speed in people with PD (1), increased dual-task cost on
stride length in PD fallers (2), and increased gait variability
in people with PD (Martini et al., under review at J Gerontol:
Med Sci), though not with freezing of gait (4). Within genetic
subgroups of people with PD, neither a leucine-rich repeat
kinase 2 mutation nor a Parkin gene mutation was associated
with worse SAI (5–7). Importantly, none of these investigations
assessed relationships among genetic status, SAI, and mobility.
A potential reason for heterogeneity of mobility disability
and of sensorimotor inhibition in PD could be the presence
of the apolipoprotein (APOE) ε4 allele or glucocerebrosidase
(GBA) gene variants (8, 9). The disparity in which specific
domains are affected could be tied to genetic differences within
PD to which specific gait or postural sway variables are
characterized. Assessing relatively independent domains of gait
or postural sway constructed by combinations of individual gait
measures could help provide a more complete picture of gait
performance (10).
The APOE ε4 allele has been associated with accelerated
decline in gait speed in healthy, older men (11). Since PD is
twice as likely to occur in men (12), it is pertinent to look at
the effect of the ε4 allele status on gait and postural sway in
people with PD, and men with PD, in particular. People with
Alzheimer’s disease, a disease inherently linked to the ε4 allele and
known to be associated with cholinergic insufficiency, have worse
SAI than people without Alzheimer’s and cholinergic medication
improves SAI, suggesting that acetylcholine loss may contribute
to poor SAI (13, 14). To date, no attempt has been made to
assess the link between ε4 allele carrier status and gait dysfunction
and their relationships to sensorimotor inhibition in people with
PD. Similarly, variants of the GBA gene are also associated with
accelerated mobility decline in the elderly and with decline in the
clinical postural instability and gait disorder phenotype in people
with PD, regardless of sex (15–17). However, no investigation has
approached sensorimotor inhibition inGBA carriers with PD and
related SAI heterogeneity to their mobility performance.
The purpose of this study was to determine if ε4 carrier orGBA
variant status is associated with reduced sensorimotor inhibition
in people with PD and whether worse sensorimotor inhibition
is associated with worse gait and postural sway performance.
We hypothesized that sensorimotor inhibition and mobility will
be worse in ε4 carriers, especially those with PD, and also in
those with PD and GBA variants. Further, we hypothesize that
decreased gait pace and increased gait variability will be related
to worse sensorimotor inhibition.
MATERIALS AND METHODS
This study was approved by Institutional Review Boards at
both University of Washington and Oregon Health & Science
University. All participants were provided and signed written
informed consent prior to participation.
Subjects and Clinical Assessments
Participants were recruited from an ongoing Pacific Udall Center
project at two sites: the University of Washington/Veterans
Affairs Puget Sound Health Care System and Oregon Health
Sciences University/Veterans Affairs Portland Health Care
System. Each participant was screened for TMS eligibility before
enrollment. Inclusion criteria included diagnosis of idiopathic
PD using the United Kingdom Parkinson’s Disease Society Brain
Bank (UKBB) criteria (18) and ability to stand unsupported
for 30 s. Exclusion criteria were inability to walk for 2min
without an assistive device, any TMS contraindication, any
musculoskeletal injury/abnormality that would affect mobility, or
any neurodegenerative disorder aside from PD. All participants
with PD were tested “ON” dopaminergic medications due to the
interaction with SAI (19), and no participants on cholinergic
medication was recruited to the TMS portion of the Pacific Udall
Center project.
The Movement Disorders Society Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) part III, the modified Hoehn &
Yahr (H&Y) score, and the Montreal Cognitive Assessment
(MoCA) were used to assess motor severity and global cognition,
respectively. A consensus committee comprised of movement
disorder neurologists and a neuropsychologist reviewed data
from each participant to determine if UKBB criteria were satisfied
and to assign a cognitive diagnosis (normal, mild cognitive
impairment, or dementia) (20).
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Genotyping
Genomic DNA was extracted from peripheral blood or saliva
samples using standard procedures. The entire GBA coding
region was screened using Sanger sequencing to capture all
known pathogenic mutations (defined as those reported in
patients with Gaucher disease) and the E326K polymorphism
(rs2230288). APOE rs429358 and rs7412, which define the ε2,
ε3, and ε4 alleles, were genotyped using TaqMan assays. All
sequencing and genotyping was performed at a single laboratory
in Seattle implementing methods previously described (8, 21).
Transcranial Magnetic Stimulation
TMS of the motor cortex was performed with a Magstim
200 (Magstim Co.). A figure-of-eight coil (external loop
diameter of 9 or 7 cm, site specific) was positioned over
the hemisphere associated with the most affected side in PD
participants and the dominant side in control participants.
Motor-evoked potentials (MEPs) were recorded from the
first dorsal interosseous muscle through disposable, Ag/AgCl
surface electrodes. Samples were amplified (gain: 2000) and
bandpass filtered (100 Hz−5 kHz) using BIOPAC MP150 system
(BIOPAC Systems, Inc) or amplified (CED 1902 isolated
preamplifier, Cambridge Electronics), converted from analog
to digital (Sampling rate 40KHz, PowerLab, ADInstruments),
and recorded for offline analysis (LabChart, ADInstruments).
Resting motor threshold was determined as the percentage of the
minimum stimulator output to elicit an MEP of 50 µV in five out
of 10 trials.
Short Latency Afferent Inhibition (SAI)
SAI was performed using a modified version of a protocol
previously described (22). A peripheral, electric conditioning
stimulus was applied over the median nerve followed by the
central test stimulus, TMS. The intensity of the conditioning
stimulus was set at the amplitude required to elicit a visible twitch
of the thenar muscles. The N20 latency was not individualized
by somatosensory evoked potentials, instead, the time of 20ms
for the N20 was used across all participants. The interstimulus
intervals (ISI) from N20 + 0ms to N20 + 5ms were applied
in a randomized block format. Five unconditioned trials were
collected within each block of conditioned trials, in a pseudo-
random order, for a total of 30 unconditioned trials. A total of
10 trials were collected for each condition and the conditioned
peak-to-peak MEP magnitudes averaged for each ISI. There was
a minimum of seven seconds between each trial. A grand mean
of the ISIs is expressed as the percentage of the unconditioned
MEP magnitudes. Participants were instructed to remain at rest,
while sitting as still as possible, and refrain from keeping their
eyes closed.
Gait and Postural Sway
Inertial sensors (Opals, APDM Inc.) were placed on each wrist
and foot, around the waist, and over the sternum to record
mobility measures (23). Gait was characterized over a 2-min
walk, over a 7-meter path, requiring 180◦ turns at the ends of the
marked path. Comprehensive measures of gait and balance were
combined into four domains based on our previous principle
component analysis using a larger cohort, which included people
with PD in this study (10). The four domains of gait were
pace/turning, rhythm, variability, and trunk movement. Postural
sway was characterized while participants stood quietly for 1min
looking straight ahead with feet width standardized by a template
(24). Similar to the gait variables, sway variables of interest were
divided into two domains, sway area/jerkiness and sway velocity.
Statistical Analyses
Data were inspected for normality using histograms and
the Kolmogorov-Smirnov test of normality. All non-normally
distributed data were log-base 10 transformed. Domain scores
were calculated by averaging the Z-scores for each gait and sway
variable. Z-scores were multiplied by −1 to reverse scaling if
needed for consistent sign in domain score calculations. A one-
way ANOVA compared PD vs. control group differences for
demographic information and SAI, with post hoc analyses Tukey
corrected for multiple comparisons. A Chi-Squared test assessed
the sex differences among the groups. Two-by-two general linear
models (GLM) were used to assess the effects of PD status and
APOE ε4 carrier status on SAI, gait domains, and sway domains,
controlling for age, sex, and collection site. The GBA group was
excluded from this GLM model. To determine if GBA variants
affected SAI and gait/postural sway within the PD cohort, we
used a separate GLM, controlling for age, sex, and collection
site. Neither of the OA groups were included in this GLM.
Participants who carried a pathogenic mutation or the E326K
polymorphism where combined into a single GBA group. Alpha
was set a priori to p < 0.05. IBM SPSS version 25 was used for
statistical analyses.
RESULTS
Ninety-three participants with idiopathic PD (53 non-carriers;
23 ε4 carriers; 17 GBA variants) and 72 healthy older adults
(OA; 45 non-carriers; 27 ε4 carriers) participated (Table 1). The
consensus committee assigned 50 participants withMCI and nine
participants with dementia in the PD, while 23 participants in
the OA group were assigned with MCI and one with dementia.
13/50 PD MCI and 2/9 PD dementia were ε4 carriers, while 9/50
PD MCI and 3/9 PD dementia were GBA variants. 10/23 OA
MCI and the one OA with dementia were ε4 carriers. Age was a
significant factor [F(1,166) = 5.75; p= 0.02], and post hoc analyses
showed the PD GBA group was significantly younger than the
rest of the groups (all p-values≤ 0.03). Only theMDS-UPDRS III
was significantly different between the PD [24.2 (12.7)] and OA
[1.9 (2.9)] groups [F(1,160) = 211.98; p < 0.001]. Post hoc analyses
reveled the OA genetic groups were not different from each other,
but both OA groups had lower MDS-UPDRS III than all the PD
groups (all p-values < 0.001).
Short-Latency Afferent Inhibition (SAI)
The PD group exhibited worse sensorimotor inhibition than the
control group [PD: 77.6 (18.2)% inhibition; OA: 69.4 (20.8)%
inhibition; F(1,157) = 8.31]. There was no significant main effect
of ε4 carrier status or interaction between PD status and genetics
on SAI.Within the PD group, there was no significant main effect
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TABLE 1 | Demographic and clinical information.
OA PD OA vs. PD
Non-Carrier ε4 Non-Carrier ε4 GBA p-value
n 45 27 53 23 17 N/A
Gender (F/M) 25/20 15/12 14/39 9/14 3/14 <0.001
Age (yrs) 69.9 (6.1) 71.4 (7.3) 68.7 (6.7) 67.5 (8.9) 62.5 (8.2) =0.018
MoCA Score 26.7 (2.6) 25.5 (3.6) 25.9 (3.2) 26.4 (2.3) 26.1 (2.7) =0.612
Modified H&Y 2.0 (1–4) 2.0 (2–3) 2.0 (1–3) N/A
MDS-UPDRS III 1.5 (2.0) 2.7 (4.2) 23.9 (12.5) 25.2 (12.7) 23.8 (13.9) <0.001
Disease Duration (yrs) 8.2 (5.2) 7.1 (4.1) 7.4 (3.3) N/A
LEDD 694.4 (481.0) 824.3 (526.4) 771.8 (656.9) N/A
Mean (standard deviation). H&Y presented as median (min-max). The modified H&Y and MDS-UPDRS III scores were significantly difference between PD and OAs, but not within the
PD or OA groups. Neither disease duration nor LEDD were significantly different among the PD genetic subgroups.
FIGURE 1 | Box/scatter plot of sensorimotor inhibition (SAI) for each group. A higher percentage is associated with less (i.e., worse) inhibition. Dashed lines represent
group means. SAI is significantly different between the PD and OA groups (p = 0.004). OA, older adults; PD, Parkinson’s disease.
of genetics for SAI. SAI for each genetic subgroup of OA and PD
are shown in Figure 1.
Gait Domains
The main effect of PD status was significant [F(4,138) = 7.49; p <
0.001] for the pace/turning domain [F(1,141) = 22.61; p < 0.001]
and variability domain [F(1,141) = 10.05; p = 0.002]. Specifically,
gait was slower and more variable in the PD than the control
group. The main effect for ε4 carrier status on gait domains was
not significant. Further, there was nomain effect for genetic status
within the PD group. The gait domain scores are presented in
Table 2. Individual gait characteristics that comprise each gait
domain are provided in Table 3 to provide greater detail about
gait performance.
Sway Domains
Similar to the gait results, the main effect for PD status was
significant [F(2,140) = 12.18; p < 0.001]. The PD group showed
larger sway area/jerkiness [F(1,141) = 24.22; p < 0.001] and larger
sway velocity [F(1,141) = 13.08; p < 0.001] compared to the
OA group. There was no main effect for ε4 carrier status on
the sway domains. The sway domain scores are presented in
Table 2. No significant main effect for genetic status within the
PD group was found for any of the sway domains. Individual
postural sway characteristics that comprise each gait domain
are provided in Table 3 to provide greater detail about postural
sway performance.
Relationship Between SAI and Mobility
Domains
SAI significantly correlated with gait variability (Pearson’s r =
0.27; p = 0.017) and trunk movement (Pearson’s r = 0.23; p
= 0.045) in the PD group. Though mobility performance was
not different genetic groups in The PD cohort, the relationships
between SAI and variability (Pearson’s r = 0.35; p = 0.010)
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TABLE 2 | Gait and postural sway domain scores.
OA PD OA vs. PD
Non-carrier ε4 Non-carrier ε4 GBA p-value
Gait Domains Pace/Turning 0.21 (0.63) 0.33 (0.64) −0.19 (0.86) −0.31 (0.90) −0.37 (0.83) <0.001
Rhythm −0.07 (0.90) −0.07 (0.80) 0.05 (0.79) −0.11 (0.96) 0.09 (1.04) =0.829
Variability −0.28 (0.60) −0.22 (0.62) 0.15 (1.00) 0.08 (0.80) 0.43 (0.97) =0.002
Trunk Movement 0.05 (0.33) −0.06 (0.32) 0.04 (0.45) −0.16 (0.35) 0.06 (0.62) =0.986
Postural Sway Domains Area/Jerkiness −0.38 (0.53) −0.44 (0.54) 0.31 (1.03) 0.18 (0.82) 0.62 (1.08) <0.001
Velocity −0.27 (0.59) −0.31 (0.75) 0.23 (0.85) 0.16 (0.95) 0.42 (0.82) <0.001
Mean (standard deviation).
TABLE 3 | Individual gait characteristics.
OA PD
Non-carrier ε4 Non-carrier ε4 GBA
Gait Pace/Turning Gait Speed (m/s) 1.1 (0.2) 1.1 (0.2) 1.1 (0.2) 1.0 (0.2) 1.0 (0.2)
Stride Length (m) 1.2 (0.1) 1.2 (0.2) 1.2 (0.2) 1.1 (0.2) 1.1 (0.2)
Foot Strike Angle (◦) 23.1 (4.0) 23.3 (4.6) 19.7 (6.3) 18.4 (6.1) 19.2 (6.4)
Turns Duration (s) 2.2 (0.3) 2.1 (0.3) 2.4 (0.4) 2.4 (0.4) 2.5 (0.4)
Peak Turn Velocity (◦/s) 180.9 (33.7) 186.3 (43.4) 160.6 (42.3) 166.4 (30.5) 151.2 (29.8)
Steps In Turn (count) 3.8 (0.6) 3.6 (0.4) 4.1 (0.8) 4.1 (0.8) 4.1 (0.8)
Rhythm Stride Time (s) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
Stance Time (% gait cycle) 60.4 (1.8) 60.3 (1. 6) 60.6 (1.7) 60.3 (1.9) 60.6 (2.1)
Swing Time (% gait cycle) 39.6 (1.8) 39.7 (1.6) 39.4 (1.7) 39.7 (1.9) 39.4 (2.1)
Variability Foot Strike Angle Variability 2.08 (0.62) 2.21 (0.73) 2.43 (1.19) 2.35 (0.73) 2.62 (0.79)
Stride Time Variability 0.02 (0.01) 0.03 (0.01) 0.03 (0.01) 0.03 (0.01) 0.03 (0.01)
Stance Time Variability 0.77 (0.18) 0.78 (0.20) 0.95 (0.39) 0.90 (0.30) 1.02 (0.34)
Swing Time Variability 0.77 (0.18) 0.78 (0.20) 0.95 (0.39) 0.90 (0.30) 1.02 (0.34)
Stride Length Variability 0.04 (0.02) 0.04 (0.02) 0.05 (0.02) 0.05 (0.02) 0.06 (0.03)
Trunk Movement Trunk Coronal RoM (◦) 5.2 (2.1) 4.6 (1.3) 5.1 (2.0) 4.4 (1.6) 5.0 (3.4)
Trunk Sagittal RoM (◦) 4.1 (0.9) 4.3 (0.8) 4.6 (1.5) 4.0 (1.0) 4.3 (1.1)
Trunk Transverse RoM (◦) 8.6 (2.8) 10.3 (3.3) 10.3 (3.7) 10.1 (4.1) 8.8 (2.7)
Postural Sway Area/Jerkiness Sway Area (m2/s5) 0.003 (0.002) 0.003 (0.002) 0.009 (0.012) 0.006 (0.006) 0.014 (0.025)
Jerk AP (m2/s5) 0.002 (0.002) 0.002 (0.002) 0.004 (0.005) 0.003 (0.003) 0.007 (0.010)
Jerk ML (m2/s5) 0.001 (0.0004) 0.0004 (0.0002) 0.003 (0.013) 0.001 (0.002) 0.008 (0.025)
RMS AP (m2/s) 0.071 (0.025) 0.070 (0.026) 0.106 (0.066) 0.091 (0.049) 0.110 (0.042)
RMS ML (m2/s) 0.021 (0.009) 0.022 (0.011) 0.043 (0.041) 0.042 (0.032) 0.052 (0.045)
Velocity Velocity AP (m/s) 0.253 (0.200) 0.235 (0.154) 0.403 (0.395) 0.356 (0.384) 0.398 (0.258)
Velocity ML (m/s) 0.077 (0.052) 0.092 (0.080) 0.165 (0.221) 0.177 (0.153) 0.217 (0.257)
Mean (standard deviation). All variability measures are presented as standard deviations.
and between SAI and trunk movement (Pearson’s r = 0.31;
p = 0.025) only remained for the PD non-carriers. SAI only
related to rhythm (Pearson’s r = 0.47; p = 0.024) for the
PD ε4 group, while SAI related to pace/turning (Pearson’s
r = −0.49; p = 0.046) and rhythm (Pearson’s r = 0.59; p
= 0.013) in the PD GBA group. There was no relationship
between SAI and postural sway domains in the PD group.
Scatter plots for significant relationships within the PD are in
Figure 2.
SAI was significantly correlated with the gait pace/turning
domain (Pearson’s r = −0.24; p = 0.046) in the OA group.
Genetic subgroup analyses revealed no relationships for the OA
group. There was no relationship between SAI and postural sway
domains for the OA group.
DISCUSSION
This study investigated how genetic factors influence
sensorimotor inhibition and mobility in OAs and people
with PD. Although people with PD had worse SAI, gait, and
balance than OAs, our results suggest that carriers of APOE ε4
allele or GBA variants do not show worse SAI, nor worse gait and
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FIGURE 2 | Scatter plots presenting the relationships between sensorimotor inhibition (SAI) and gait domains for the PD genetic subgroups only. Lines indicate the
best fit line. A higher percentage (SAI) is associated with less (i.e., worse) inhibition. Higher domain scores indicate faster pace/turning, increased rhythm (increased
times for stride, stance, and swing phases), and greater variability. r is the Pearson’s correlation coefficient for the relationship between SAI and relevant gait domain
score. All correlations presented are significant (p < 0.05).
postural sway than non-carriers. However, worse sensorimotor
inhibition was associated with worse gait (but not standing
postural sway) in all genetic subgroups of PD, but not OA
groups. In fact, heterogeneity of specific domains of gait most
affected in people with PD (decreased pace/turning, increased
variability, and increased rhythm) depended upon the genetic
status of the PD group. Thus, cortical sensorimotor inhibition
appears more critical for gait than for standing balance and more
critical for people with PD than for older adults without PD.
We previously reported (Martini et al., under review at
J Gerontol: Med Sci) that people with PD had significant
mobility dysfunction compared to healthy OAs, including slower
gait speed/turn velocity and greater gait variability, postural
sway area/jerkiness, and sway velocity, consistent with previous
investigations (25–27). Our previous report included 81 of the 93
people with PD and 69 of the 72 OAs in this report (Martini et
al., under review at J Gerontol: Med Sci). The current study used
mobility domain scores, based on principal component analysis
(10), rather than individual metrics of postural sway and gait,
which can lead to inflated, type-one errors.
Genetic status was not a significant factor for gait or sway
performance in people with idiopathic PD, contrary to our
hypothesis.GBA is a strong risk factor for PD and particularly PD
with more severe cognitive and gait and balance decline than PD
without GBA (8, 9, 17). Since ACh is known to be important for
cognition (28) and cognition is known to be related to gait speed
in both older adults and people with PD (1, 29), we expected
people with PD who had GBA variants to show worse SAI as
well as worse balance and gait than non-carriers A larger cohort
of people with PD and GBA variants (n = 58) from our PUC
investigation reported that people with PD and GBA a variant
had a quicker progression through motor and cognitive decline
than non—GBA variant PD (17). Our subset from that sample
of people with GBA variants is smaller, with milder parkinsonian
symptoms based on the MDS-UPDRS III (17).
Like GBA, APOE ε4 allele status was not associated with worse
mobility. The APOE ε4 allele is not a risk factor for PD, but
it is a risk factor for dementia. Since decline in cognition is
associated with decline in balance control with aging and with PD
(30, 31), we hypothesized that people with PD who are carriers of
APOE ε4 allele would have more loss of ACh than non-carriers
and therefore show worse SAI and worse balance and gait than
non-carriers. In fact, APOE ε4 allele carriers with PD have been
shown to have worse executive function than non-carriers and
executive function has been associated with slower gait speed
(32) in otherwise healthy OAs and with increased variability (33)
and Alzheimer’s disease. However, we found no evidence that
APOE ε4 status in people with PD was associated with worse
SAI nor worse balance or gait. Though, the MoCA scores for the
genetic subsets were not statistically different and were above the
cognitive impairment cut off score of 23, which was reported to
have higher sensitivity and specificity than higher cut off scores
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(34). Longitudinal studies, which incorporate a comprehensive
cognitive batteries, are needed to determine if PD APOE ε4
carriers would show faster progression of their balance and gait
disorders over time, similar to older men without PD (11).
Genetic status was not a significant factor for gait or sway
performance in healthy OAs. This contradicts previous reports
that observed smaller stride length in male OA ε4 allele carriers
than non-carriers (35). Longitudinal analyses reported similar
observations, with an accelerated decline in gait speed and
increase in gait variability in ε4 allele carriers over 1 year (11, 36).
The accelerated decline in gait speed was only noted for OA
males (11), which suggests that there may be a sex influence
on ε4 allele carrier status and increased risk of gait dysfunction
over time. Despite the ε4 allele being linked to an increased risk
for dementia (37), a separate study found no change in MoCA
scores over a year (36), suggesting an increased motor decline
not directly linked to cognitive decline. Thus, assessing changes
in gait and balance performance across time may be a better
indicator of mobility dysfunction in male ε4 allele carriers than
a cross-sectional approach.
Consistent with previous investigations, we show that people
with PD do not inhibit the motor cortex as much with a sensory
afferent signal compared to OAs (1, 2, 38) (Martini et al., under
review at J Gerontol: Med Sci). GBA and ε4 allele status did
not affect SAI, similar to leucine-rich repeat kinase 2 mutation
nor a Parkin gene mutation (5–7). Sensorimotor inhibition, as
measured with SAI, is thought to reflect levels of cortical ACh
neurotransmitter activity (3), The basis for the notion that SAI
is mediated by cholinergic activity is that SAI is impaired in
Alzheimer’s disease, a disorder known to result in loss of ACh,
and because medications that increase ACh also improve the SAI
(13, 39–41). Recent theories of the neural pathways responsible
for SAI suggests that the subthalamic nucleus or paramedian
thalamic nuclei are responsible for inhibition of the primary
motor cortex either directly, or indirectly, via the primary sensory
cortex (38, 42). The theoretical pathway that incorporates the
subthalamic nucleus was posited as a result of the modulatory
effects of deep brain stimulation on the subthalamic nucleus
in human and animal studies (38). The theoretical pathway,
involving the paramedian thalamic nuclei is based off of the
connections between SAI and cholinergic pathways as observed
in drug and disease studies (13, 41, 43). Importantly, dopamine
replacement therapy is linked to worse SAI in people with PD
(19), suggesting that cholinergic activity is not the only influence
on the inhibitory response recorded in SAI. A reciprocal circuit
among the basal ganglia (e.g., subthalamic nucleus), thalamus,
and cortex could be the primary neural pathway responsible
for SAI, as a measure of sensorimotor inhibition (38, 42, 44).
Although the specific neural mechanisms underlying the SAI
are a debated, a recent review of the topic details the complex
neural pathways between the basal ganglia and motor cortices,
moderated by thalamus that may be involved (44).
The effect of PD status on SAI suggests that the pathway
between the substantia nigra pars compacta, ventral thalamus,
and motor regions are responsible for the inhibitory response
observed. The ventral lateral thalamic nuclei receive input from
the basal ganglia, the substantia nigra in particular, as well as
proprioceptive input (44). The substantia nigra degeneration
with concomitant loss of dopamine neurotransmitter is
responsible for Parkinsonism but dopamine replacement therapy
does not alleviate all gait and balance impairments in PD, and
may even worsen some domains of mobility (45–47). In addition,
proprioception is a critical sensory input for control of gait and
balance and is known to be impaired in PD (48).
In this same cohort of people with PD, we previously reported
that sensorimotor inhibition was specifically related to stride
length variability, foot strike angle variability, and jerkiness of
sway (Martini et al., under review at J Gerontol: Med Sci). The
relationship between SAI and gait domains, but not with balance
domains, observed here suggests that sensorimotor inhibition
is more critical for control of dynamic balance, than static,
standing balance, which may be more controlled by thalamic
and brainstemmechanisms (49). The relationship between worse
sensorimotor increased gait variability could be an indicator of
decreased gait automaticity, with increased reliance on frontal
cortical areas (50, 51). Indeed, increased frontal cortex activity
and gait variability is found in people with PD and freezing of
gait (52). Ultimately, loss of gait automaticity is related to an
increased risk of falls across gait disorders (53).
SAI was differently related to gait domains across the genetic
subgroups in the PD group. Worse SAI was related to increased
gait variability and trunkmovement in the PD non-carrier group,
which may reflect impaired dynamic balance as postural stepping
responses to correct lateral body center of mass displacements
interrupt steady state rhythmic gait (47, 54, 55). SAI was
significantly related to increased rhythm in the PD ε4 group.
Increased rhythm, which is derived from stride time, stance time,
and swing time, suggests that the PD ε4 group has longer stride
and stance times when sensorimotor inhibition is worse. Lastly,
SAI related to decreased pace/turning and increased rhythm in
the PD GBA variant group. This relationship may permit SAI to
be a marker of slowed gait performance due to bradykinesia or
an early adoption of a conservative gait strategy, in an attempt to
prevent falls.
SAI was associated with the gait pace/turning domain in
older adults, but there were no effects of the ε4 allele on gait
or the relationship between sensorimotor inhibition and gait in
the OA group. Previous investigations found no difference in
sensorimotor inhibition between otherwise healthy young and
OA groups (56, 57). However, both sensorimotor inhibition and
gait speed were reduced in OA fallers compared to OA non-
fallers (2). Adopting a slower gait pace may be a compensatory
mechanism for poorer sensorimotor inhibition as a means
for preventing falls. These results suggest that OAs with low
sensorimotor inhibition may need an intervention to help reduce
potential falls. SAI may be a quick, non-invasive assessment
for identifying OAs who could benefit from an intervention.
Though, the appropriate type of intervention would depend on
the neurological mechanism responsible for SAI.
There are potential limitations to the interpretation of the
results of this investigation. TMS was collected at two different
academic centers. However, we controlled for this statistically and
the SAI is calculated as a percentage of each participant’s own
MEPs, mitigating device or administrator influence. Further, we
created a site variable and used it as a covariate in analyses. The
effects of sex on SAI are not fully understood, so we adjusted
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for sex statistically. The sample sizes for the ε4 allele carriers
and the GBA carriers were small. We attempted to mitigate
this by analyzing the ε4 allele carriers and non-carriers across
PD status, and ε4 allele and GBA variant status within the PD
group only. GBA variants only exist in 8% of the idiopathic
PD population, which makes this population difficult to recruit.
The inclusion criteria requiring participants to stand for at least
30 s unassisted could have biased the sample away from more
severely affected ε4 allele carriers and GBA carriers. Using the
first dorsal interosseous muscle to measure SAI, opposed to a
lower-limb muscle, when attempting to elucidate relationships
between SAI and gait/sway characteristics is a limitation that may
affect the generalizability of the results. However, previous groups
implemented the same SAI methodology when relating SAI to
gait performance (1, 2, 4).
Among people with PD, APOE and GBA genetic status did
not affect either sensorimotor inhibition or measures of gait
and postural sway. However, dependent on genetic status, worse
sensorimotor inhibition was related to increased gait variability,
impaired temporal rhythm and/or slower gait pace/turning in
this PD group. This dichotomy of the relationships between
sensorimotor inhibition and gait domains for people with PD
with different genetic status could be related to the dependence
of each group on cortical control of different aspects of gait.
Longitudinal studies could elucidate more robust relationships
between sensorimotor inhibition and mobility, while factoring
in the role of cognition, in the ε4 and GBA variant subgroups of
people with PD.
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